Ischemic Cerebral Stroke Prevention Therapeutics Market Analysis, Recent Trends and Regional Growth Forecast by 2027

Ischemic Cerebral Stroke Prevention Therapeutics Market: Drivers and Restraints

Increase in the number of cerebral stroke cases across the globe coupled with high prices for AIS therapy contribute towards significant growth of ischemic cerebral stroke prevention therapeutics market worldwide. In addition, growing prevalence of acute ischemic strokes among young population is anticipated to fuel the demand for surgical procedures, thereby in order to avoid the surgery demand for ischemic cerebral stroke prevention therapeutics will grow significantly in the next five to six years. However, limited availability of efficient drugs is restricting the market growth. Also, ischemic attack survivors are prone to another attack, thereby increased morbidity and mortality. This is leading to increased concerns for prevention therapeutics, resulting in overall ischemic cerebral stroke prevention therapeutics market growth.

When an obstruction occurs in the blood vessel that supplies blood to the brain, it is known as ischemic stroke. This stroke accounts for around 87 percent of the total stroke cases and the main cause leading to ischemic stroke is uncontrolled hypertension. Basically, ischemic stroke is due to weak blood vessel, which gets rupture and leads to blood spill into the brain tissue. There are two types of ischemic cerebral strokes namely embolic or thrombotic. During atherosclerosis, when artery is blocked by a blood clot, resulting into fatty deposits. However, when a blood clot is formed outside the brain and then travels to the blood stream, it is known as embolus (emboli) stroke. Globally, technological advancements leading to development of advanced surgical devices coupled with increasing prevalence of ischemic strokes among people has led to demand for better and efficient stroke management or treatment. Major goal of ischemic cerebral stroke prevention to restore flow of blood as quickly as possible. Conventional ischemic stroke treatments include intravenous thrombolytic therapy and intra-arterial mechanical thrombectomy, which includes stent retriever devices. According to American Stroke Association, few recommendations related to prevention of ischemic cerebral stroke include sleep apnea screening, smoking cessation, and usage of anticoagulants orally especially patients suffering with non-valvular atrial fibrillation.

It is essential to prevent the stroke as this is the deadly condition and is an age related. This can be basically controlled in two ways, Primary Prevention of Stroke and the other is Secondary Prevention of Stroke.

Primary Prevention of Stroke can be done with the administration of antihypertensive drugs, anticoagulants-warfarin; antiplatelet agents, and statins. The prominent cause of Ischemic Cerebral Stroke are smoking, hypertension, Diabetes, Sickle cell disease, Body fat etc. There are also some home primary remedies like self-monitoring of blood pressure in hypertensive patients and proper sleep.

To remain ahead of your competitors, request for a sample –

Ischemic Cerebral Stroke Prevention Therapeutics: Region-wise Outlook

Geographically, the global intravenous ultrasound systems market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Among all the regions, North America will continue to lead the global market for ischemic cerebral stroke prevention therapeutics. This is attributed to increasing cerebral stroke cases in the region. Geriatric population in Europe and Asia Pacific, who are prone to cerebral stroke offer opportunity for ischemic cerebral stroke prevention therapeutics market in the regions.

Ischemic Cerebral Stroke Prevention Therapeutics: Key Players

Key players operating in the global intravenous ultrasound systems market are Johnson & Johnson (Cordis Corporation), Boston Therapeutics, Inc., Edge Therapeutics, Inc., Zocere, Inc., Lundbeck, ThromboGenics, Vernalis, Bayer, Bristol-Myers Squibb, and Boehringer Ingelheim.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.

Ischemic Cerebral Stroke Prevention Therapeutics Market: Segmentation

The global market for ischemic cerebral stroke prevention therapeutics is broadly classified on the basis of drug type, and end user.

Based on drug type, the ischemic cerebral stroke prevention therapeutics market has been segmented as follows:

  • Anticoagulation Therapy
  • Warfarin
  • Heparin
  • Revascularization
  • Reperfusion
  • Eminase
  • Retavase
  • Streptase
  • Others
  • Antiplatelet
  • Aspirin
  • Clopidogrel
  • Dipyridamole
  • Ticlopidine
  • Neuroprotective
  • Acetyl-L-carnitine
  • Citicoline (CDP-Choline)

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert –

Based on end user, theischemic cerebral stroke prevention therapeutics market has been segmented as follows:

  • Hospitals
  • Clinics
  • Palliative Care
  • Ambulatory Surgery Centers

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries:
For Media Enquiries:

Leave a comment

Your email address will not be published. Required fields are marked *